Researchers have presented promising results from a new cancer treatment called RP2, which uses an engineered herpes virus to target advanced solid tumors. In a recent trial, RP2 was tested alone and in combination with another drug, nivolumab, on patients with various types of hard-to-treat cancers. The results showed that about 19% of patients responded positively to RP2 alone, while the combination treatment had a slightly higher response rate of 19.1%. Notably, the treatment was well-tolerated, with manageable side effects like mild fever and fatigue.

This discovery is significant for anyone concerned about cancer, particularly those with advanced solid tumors who may have exhausted other treatment options. The study involved 85 patients with cancers such as melanoma, colorectal cancer, and pancreatic cancer, many of whom had already undergone multiple treatments. The response rates indicate that RP2 could offer a new avenue for treatment, potentially improving outcomes for people facing these challenging conditions. The durability of the responses is also encouraging, with some patients experiencing lasting benefits for over 22 months.

The research is still in the early stages, being a first-in-human trial with a relatively small number of participants. While the results are promising, they are not yet definitive proof of effectiveness in a larger population. A randomized Phase 2/3 trial is underway to further evaluate RP2’s effectiveness, particularly in uveal melanoma. As the study progresses, it will be essential to keep an eye on these developments for potential future treatment options.

Source: globenewswire.com